---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-311202"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:03:45.814744+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Terns reports 64% MMR rate in Phase 1 CARDINAL trial of TERN-701 in CML; selects 320/500 mg RP2D

## Summary
- Overall MMR rate of 64% (18/28) achieved by 24 weeks; cumulative MMR rate 74% (28/38).
- At doses >=320 mg QD (RP2D), MMR achievement 75% (18/24) by 24 weeks; DMR rate 36% (10/28).
- Safety: 87% patients on treatment; no DLTs; low Grade 3+ cytopenia (<10%); common TEAEs diarrhea, headache, nausea.
- Enrollment surpassed 85 patients; company plans pivotal Phase 3 trials in 2L+ and 1L CML in 2026.

## SEC filing metadata
- accession: 0001193125-25-311202
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312525311202/0001193125-25-311202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312525311202/d19462d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-311202
- JSON: https://secwatch.observer/filing/0001193125-25-311202.json
- Plain text: https://secwatch.observer/filing/0001193125-25-311202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.